EUVIMEDOpdag EUVIMED
Crossref

A Utility-Based Bayesian Phase I–II Design for Immunotherapy Trials with Progression-Free Survival End Point

Beibei Guo, Yeonhee Park, Suyu Liu

Journal of the Royal Statistical Society Series C: Applied Statistics · 2019-02-01 · 68 (2) · 411-425

DOI: 10.1111/rssc.12288 ↗

At a glance

Journal article in Journal of the Royal Statistical Society Series C: Applied Statistics, published online on 2018-05-18. Written by Beibei Guo and 2 co-authors. Cited 20 times so far (Crossref); 28 references.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Immunotherapy has been hailed as the biggest breakthrough for treating cancer since the first development of chemotherapy. The new features of immunotherapy make the traditional clinical trial paradigm increasingly inefficient and dysfunctional. We propose a Bayesian phase I–II design for immunotherapy trials called BDFIT to find the optimal biological dose (OBD). We jointly model the toxicity outcome, progression-free survival (PFS) and immune response. PFS and toxicity are used as the primary end points to determine the OBD, whereas the immune response is used as an ancillary end point to screen out futile doses quickly and to predict the PFS when needed. A utility function is formulated to account for the risk–benefit trade-off and to quantify the desirability of the dose. During the trial, based on accumulating data, the estimates of the model and dose desirability are continuously updated and used to guide the dose assignment and to select the OBD. The simulation study shows that the BDFIT design has desirable operating characteristics.

Cite

APA

Guo, B., Park, Y., & Liu, S. (2019). A Utility-Based Bayesian Phase I–II Design for Immunotherapy Trials with Progression-Free Survival End Point. Journal of the Royal Statistical Society Series C: Applied Statistics, 68(2), 411-425. https://doi.org/10.1111/rssc.12288

Vancouver

Guo B, Park Y, Liu S. A Utility-Based Bayesian Phase I–II Design for Immunotherapy Trials with Progression-Free Survival End Point. Journal of the Royal Statistical Society Series C: Applied Statistics. 2019;68(2):411-425. doi:10.1111/rssc.12288

BibTeX
@article{Guo2019,
  author = {Guo, Beibei and Park, Yeonhee and Liu, Suyu},
  title = {A Utility-Based Bayesian Phase I–II Design for Immunotherapy Trials with Progression-Free Survival End Point},
  journal = {Journal of the Royal Statistical Society Series C: Applied Statistics},
  year = {2019},
  volume = {68},
  number = {2},
  pages = {411--425},
  doi = {10.1111/rssc.12288}
}
Start for free →